Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

Astellas’ Xospata wins AML approval in Europe
The European Commission has approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as a monotherapy for relapsed or refractory acute myelogenous leukemia with an FLT3 Mutation. The

Read the full 338 word article

User Sign In